CAFERGOT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cafergot, and what generic alternatives are available?
Cafergot is a drug marketed by Novartis and Sandoz and is included in three NDAs.
The generic ingredient in CAFERGOT is caffeine; ergotamine tartrate. There are eleven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the caffeine; ergotamine tartrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CAFERGOT?
- What are the global sales for CAFERGOT?
- What is Average Wholesale Price for CAFERGOT?
Summary for CAFERGOT
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 3 |
| Clinical Trials: | 3 |
| DailyMed Link: | CAFERGOT at DailyMed |
Recent Clinical Trials for CAFERGOT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Rajavithi Hospital | Phase 3 |
| Stanford University | Phase 2 |
| Vanderbilt University Medical Center | Phase 1 |
US Patents and Regulatory Information for CAFERGOT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | CAFERGOT | caffeine; ergotamine tartrate | SUPPOSITORY;RECTAL | 009000-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | CAFERGOT | caffeine; ergotamine tartrate | TABLET;ORAL | 006620-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sandoz | CAFERGOT | caffeine; ergotamine tartrate | TABLET;ORAL | 084294-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
